Preliminary data from a Phase 3 clinical trial, fliGHt, evaluating the safety and tolerability of Ascendis Pharma's (NASDAQ:ASND) TransCon Growth Hormone in patients with pediatric growth hormone deficiency previously treated with commercially available daily growth hormone therapies showed a comparable safety profile.